Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clonidine/oxybutynin - Orient Pharma

Drug Profile

Clonidine/oxybutynin - Orient Pharma

Alternative Names: DL 06001; OP-014; SMT D001

Latest Information Update: 25 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator DanioLabs
  • Developer Orient Pharma
  • Class Analgesics; Antiglaucomas; Antimigraines; Antispasmodics; Carbocyclic acids; Centrally-acting antihypertensives; Imidazolines; Mandelic acids; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor agonists; Cholinergic receptor antagonists; Imidazoline receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Sialorrhoea

Most Recent Events

  • 25 Jan 2019 Clonidine/oxybutynin is not yet available for Sialorrhoea in Australia and Singapore (PO)
  • 25 Jan 2019 No recent reports of development identified after preregistration for Sialorrhoea in USA, European Union, Canada, China, China, Japan, Philippines, Hong Kong, Malaysia, India, New Zealand, South Korea (PO)
  • 04 Feb 2016 Preregistration for Sialorrhoea in European Union (PO) before February 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top